Clinical Trial

NASH AMPK Exercise Dosing (AMPED) Trial

Study acronym: AMPED
Completed
View on ClinicalTrials.gov →
Summary
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-13
notable Enrollment reduced: 45 -> 20 participants 2026-08-13
notable Primary completion moved earlier: 2026-05-31 -> 2026-02-10 2026-08-13
minor Completion moved earlier: 2026-07-15 -> 2026-02-10 2026-08-13
Trial Details
NCT Number NCT04987879
Lead Sponsor Milton S. Hershey Medical Center
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions NAFLD
Enrollment 20 participants
Start Date 2022-08-30
Primary Completion 2026-02-10 (estimated)
Study Completion 2026-02-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-12